文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Herbal therapy for ameliorating nonalcoholic fatty liver disease via rebuilding the intestinal microecology.

作者信息

Yang Xiao-Fang, Lu Ming, You Lijiao, Gen Huan, Yuan Lin, Tian Tianning, Li Chun-Yu, Xu Kailiang, Hou Jie, Lei Ming

机构信息

Critical Care Medicine, Seventh Peoples Hospital, Affiliated to Shanghai University of TCM, Shanghai, 200137, China.

Trauma Emergency Center, The Seventh Peoples Hospital of Shanghai University of Traditional Chinese Medicine, Shanghai, 200137, China.

出版信息

Chin Med. 2021 Jul 27;16(1):62. doi: 10.1186/s13020-021-00470-x.


DOI:10.1186/s13020-021-00470-x
PMID:34315516
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8314451/
Abstract

The worldwide prevalence of nonalcoholic fatty liver disease (NAFLD) is increasing, and this metabolic disorder has been recognized as a severe threat to human health. A variety of chemical drugs have been approved for treating NAFLD, however, they always has serious side effects. Chinese herbal medicines (CHMs) have been widely used for preventing and treating a range of metabolic diseases with satisfactory safety and effective performance in clinical treatment of NAFLD. Recent studies indicated that imbanlance of the intestinal microbiota was closely associated with the occurrence and development of NAFLD, thus, the intestinal microbiota has been recognized as a promising target for treatment of NAFLD. In recent decades, a variety of CHMs have been reported to effectively prevent or treat NAFLD by modulating intestinal microbiota to further interfer the gut-liver axis. In this review, recent advances in CHMs for the treatment of NAFLD via rebuilding the intestinal microecology were systematically reviewed. The key roles of CHMs in the regulation of gut microbiota and the gut-liver axis along with their mechanisms (such as modulating intestinal permeability, reducing the inflammatory response, protecting liver cells, improving lipid metabolism, and modulating nuclear receptors), were well summarized. All the knowledge and information presented here will be very helpful for researchers to better understand the applications and mechanisms of CHMs for treatment of NAFLD.

摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b0b3/8314451/3574cdefdc5b/13020_2021_470_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b0b3/8314451/6c11be662184/13020_2021_470_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b0b3/8314451/3349d0823030/13020_2021_470_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b0b3/8314451/6ec66c509d1e/13020_2021_470_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b0b3/8314451/3ee32bb93aa1/13020_2021_470_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b0b3/8314451/29821cddded0/13020_2021_470_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b0b3/8314451/3574cdefdc5b/13020_2021_470_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b0b3/8314451/6c11be662184/13020_2021_470_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b0b3/8314451/3349d0823030/13020_2021_470_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b0b3/8314451/6ec66c509d1e/13020_2021_470_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b0b3/8314451/3ee32bb93aa1/13020_2021_470_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b0b3/8314451/29821cddded0/13020_2021_470_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b0b3/8314451/3574cdefdc5b/13020_2021_470_Fig6_HTML.jpg

相似文献

[1]
Herbal therapy for ameliorating nonalcoholic fatty liver disease via rebuilding the intestinal microecology.

Chin Med. 2021-7-27

[2]
Lycium barbarum polysaccharide combined with aerobic exercise ameliorated nonalcoholic fatty liver disease through restoring gut microbiota, intestinal barrier and inhibiting hepatic inflammation.

Int J Biol Macromol. 2021-7-31

[3]
Protective effect of quercetin on high-fat diet-induced non-alcoholic fatty liver disease in mice is mediated by modulating intestinal microbiota imbalance and related gut-liver axis activation.

Free Radic Biol Med. 2017-1

[4]
Dietary Polyphenols to Combat Nonalcoholic Fatty Liver Disease via the Gut-Brain-Liver Axis: A Review of Possible Mechanisms.

J Agric Food Chem. 2021-3-31

[5]
Gut microbiota: novel therapeutic target for nonalcoholic fatty liver disease.

Expert Rev Gastroenterol Hepatol. 2019-1-25

[6]
Lactobacillus plantarum NA136 ameliorates nonalcoholic fatty liver disease by modulating gut microbiota, improving intestinal barrier integrity, and attenuating inflammation.

Appl Microbiol Biotechnol. 2020-6

[7]
Diammonium Glycyrrhizinate Protects against Nonalcoholic Fatty Liver Disease in Mice through Modulation of Gut Microbiota and Restoration of Intestinal Barrier.

Mol Pharm. 2018-8-2

[8]
Probiotics as a complementary therapeutic approach in nonalcoholic fatty liver disease.

World J Hepatol. 2015-3-27

[9]
Interaction of gut microbiota with dysregulation of bile acids in the pathogenesis of nonalcoholic fatty liver disease and potential therapeutic implications of probiotics.

J Cell Biochem. 2018-11-15

[10]
Chinese Herbal Medicines for Coronary Heart Disease: Clinical Evidence, Pharmacological Mechanisms, and the Interaction with Gut Microbiota.

Drugs. 2024-2

引用本文的文献

[1]
A Literature Review of Glutathione Therapy in Ameliorating Hepatic Dysfunction in Non-Alcoholic Fatty Liver Disease.

Biomedicines. 2025-3-6

[2]
Drug Advances in NAFLD: Individual and Combination Treatment Strategies of Natural Products and Small-Synthetic-Molecule Drugs.

Biomolecules. 2025-1-17

[3]
The gut-liver axis in fatty liver disease: role played by natural products.

Front Pharmacol. 2024-4-15

[4]
Ginsenoside Rk2, a dehydroprotopanaxadiol saponin, alleviates alcoholic liver disease via regulating NLRP3 and NLRP6 inflammasome signaling pathways in mice.

J Pharm Anal. 2023-9

[5]
A herb mixture to ameliorate non-alcoholic fatty liver in rats fed a high-fat diet.

Heliyon. 2023-8-2

[6]
Gut Microbiota Modulates the Protective Role of Ginsenoside Compound K Against Sodium Valproate-Induced Hepatotoxicity in Rat.

Front Microbiol. 2022-7-7

本文引用的文献

[1]
Microbiome connections with host metabolism and habitual diet from 1,098 deeply phenotyped individuals.

Nat Med. 2021-2

[2]
Ferulic acid ameliorates intrahepatic triglyceride accumulation in vitro but not in high fat diet-fed C57BL/6 mice.

Food Chem Toxicol. 2021-3

[3]
Synthesis, Photoisomerization, Antioxidant Activity, and Lipid-Lowering Effect of Ferulic Acid and Feruloyl Amides.

Molecules. 2020-12-28

[4]
Emerging targets and potential therapeutic agents in non-alcoholic fatty liver disease treatment.

Eur J Med Chem. 2020-4-18

[5]
Pivotal Role of the Interaction Between Herbal Medicines and Gut Microbiota on Disease Treatment.

Curr Drug Targets. 2021

[6]
Gut microbiota and human NAFLD: disentangling microbial signatures from metabolic disorders.

Nat Rev Gastroenterol Hepatol. 2020-3-9

[7]
Herbal drug discovery for the treatment of nonalcoholic fatty liver disease.

Acta Pharm Sin B. 2020-1

[8]
Deciphering the metabolic fates of herbal constituents and the interactions of herbs with human metabolic system.

Chin J Nat Med. 2019-11

[9]
Amelioration of non-alcoholic steatohepatitis by Qushi Huayu decoction is associated with inhibition of the intestinal mitogen-activated protein kinase pathway.

Phytomedicine. 2019-11-10

[10]
Changes of gut microbiota during silybin-mediated treatment of high-fat diet-induced non-alcoholic fatty liver disease in mice.

Hepatol Res. 2020-1

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索